Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 1 Irbesartan decreases susceptibility to low-density lipoprotein (LDL) oxidation in patients with coronary artery disease (CAD). Patients with CAD were placed on placebo or irbesartan (150 mg/day) for a 12-week period. Serum samples were collected at the start of the study (0 weeks) and at 4 and 12 weeks of treatment. The LDL was isolated by centrifugation, and rate of oxidation was measured by spectrophotometric analysis as described in the Methods section. The p value, as determined by analysis of variance, was 0.027 for time, <0.0001 for group and 0.014 for the group-time interaction. Black diamond = placebo; black square = irbesartan; *p < 0.05 = difference between 0 weeks and 4 or 12 weeks within each group; #p < 0.05 = difference between placebo and irbesartan groups.
|
